HRP20120960T1 - Formulacije za lijeäśenje raka - Google Patents
Formulacije za lijeäśenje raka Download PDFInfo
- Publication number
- HRP20120960T1 HRP20120960T1 HRP20120960AT HRP20120960T HRP20120960T1 HR P20120960 T1 HRP20120960 T1 HR P20120960T1 HR P20120960A T HRP20120960A T HR P20120960AT HR P20120960 T HRP20120960 T HR P20120960T HR P20120960 T1 HRP20120960 T1 HR P20120960T1
- Authority
- HR
- Croatia
- Prior art keywords
- preparation
- cyclodextrin
- cancer
- accordance
- hydroxypropyl
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title claims 8
- 201000011510 cancer Diseases 0.000 title claims 8
- 238000009472 formulation Methods 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 229920000858 Cyclodextrin Polymers 0.000 claims 12
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 claims 12
- ODLHGICHYURWBS-LKONHMLTSA-N trappsol cyclo Chemical compound CC(O)COC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)COCC(O)C)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1COCC(C)O ODLHGICHYURWBS-LKONHMLTSA-N 0.000 claims 6
- 239000007864 aqueous solution Substances 0.000 claims 4
- MDOJTZQKHMAPBK-UHFFFAOYSA-N 4-iodo-3-nitrobenzamide Chemical compound NC(=O)C1=CC=C(I)C([N+]([O-])=O)=C1 MDOJTZQKHMAPBK-UHFFFAOYSA-N 0.000 claims 3
- 206010006187 Breast cancer Diseases 0.000 claims 3
- 208000026310 Breast neoplasm Diseases 0.000 claims 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 3
- 206010033128 Ovarian cancer Diseases 0.000 claims 3
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 3
- 229910019142 PO4 Inorganic materials 0.000 claims 3
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 3
- 201000005202 lung cancer Diseases 0.000 claims 3
- 208000020816 lung neoplasm Diseases 0.000 claims 3
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 3
- 201000002528 pancreatic cancer Diseases 0.000 claims 3
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims 3
- 239000010452 phosphate Substances 0.000 claims 3
- 238000002347 injection Methods 0.000 claims 2
- 239000007924 injection Substances 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 229940097346 sulfobutylether-beta-cyclodextrin Drugs 0.000 claims 2
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
- 230000003612 virological effect Effects 0.000 claims 1
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
Claims (18)
1. Pripravak u obliku vodene otopine, koji sadrži 4-jod-3-nitrobenzamid, ili njegovu farmaceutski prihvatljivu sol: ciklodekstrin, koji je hidroksipropil-β-ciklodekstrin ili sulfobutil-eter-β-ciklodekstrin, te fiziološki prihvatljivi injekcijski pufer, naznačen time što je namijenjen upotrebi u liječenju raka ili virusnog stanja.
2. Pripravak u skladu s patentnim zahtjevom 1, naznačen time što rak je iz skupine koju čine leukemija, rak dojke, rak jajnika, rak pluća, rak mokraćnog mjehura, rak prostate, rak gušterače i rak vrata maternice.
3. Pripravak u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što rak je iz skupine koju čine rak dojke, rak jajnika, rak pluća i rak gušterače.
4. Pripravak u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što rak je rak dojke.
5. Pripravak u skladu s bilo kojim od patentnih zahtjeva 1 do 3, naznačen time što rak je rak jajnika.
6. Pripravak u skladu s bilo kojim od patentnih zahtjeva 1 do 3, naznačen time što rak je rak pluća.
7. Pripravak u skladu s bilo kojim od patentnih zahtjeva 1 do 3, naznačen time što rak je rak gušterače.
8. Pripravak u obliku vodene otopine za injekciju, naznačen time što sadrži 4-jod-3-nitrobenzamid, ili njegovu farmaceutski prihvatljivu sol, fiziološki prihvatljivi pufer, te ciklodekstrin, koji je hidroksipropil-β-ciklodekstrin ili sulfobutil-eter-β-ciklodekstrin.
9. Pripravak namijenjen upotrebi u skladu s patentnim zahtjevom 1 ili pripravak u skladu s patentnim zahtjevom 8, naznačen time što je ciklodekstrin prisutan u navedenoj vodenoj otopini u koncentraciji od 25% do 40% (tež./vol.) pripravka.
10. Pripravak namijenjen upotrebi u skladu s patentnim zahtjevom 1 ili pripravak u skladu s patentnim zahtjevom 8, naznačen time što je ciklodekstrin prisutan u navedenoj vodenoj otopini u koncentraciji od 25% ili 40% (tež./vol.) pripravka.
11. Pripravak namijenjen upotrebi u skladu s patentnim zahtjevom 1 ili pripravak u skladu s patentnim zahtjevom 8, naznačen time što je ciklodekstrin hidroksipropil-β-ciklodekstrin.
12. Pripravak namijenjen upotrebi u skladu s patentnim zahtjevom 1 ili pripravak u skladu s patentnim zahtjevom 8, naznačen time što je ciklodekstrin 2-hidroksipropil-β-ciklodekstrin.
13. Pripravak namijenjen upotrebi u skladu s patentnim zahtjevom 1 ili pripravak u skladu s patentnim zahtjevom 8, naznačen time što je ciklodekstrin Kleptose™.
14. Pripravak namijenjen upotrebi u skladu s patentnim zahtjevom 1 ili pripravak u skladu s patentnim zahtjevom 8, naznačen time što je ciklodekstrin prisutan u koncentraciji od 25% (tež./vol.).
15. Pripravak namijenjen upotrebi u skladu s patentnim zahtjevom 1 ili pripravak u skladu s patentnim zahtjevom 8, naznačen time što je ciklodekstrin prisutan u koncentraciji od 25%, a pufer je 10 mM fosfat s pH 7,4.
16. Pripravak namijenjen upotrebi u skladu s patentnim zahtjevom 1 ili pripravak u skladu s patentnim zahtjevom 8, naznačen time što je težinski omjer između ciklodekstrina i 4-jod-3-nitrobenzamida od 1:100 do 5000:1.
17. Pripravak namijenjen upotrebi u skladu s patentnim zahtjevom 1, naznačen time što je ciklodekstrin 2-hidroksipropil-β-ciklodekstrin i prisutan je u koncentraciji od 25%, a pufer je 10 mM fosfat s pH 7,4.
18. Pripravak u skladu s patentnim zahtjevom 8, naznačen time što je ciklodekstrin 2-hidroksipropil-β-ciklodekstrin i je prisutan u koncentraciji od 25%, a pufer je 10 mM fosfat s pH 7,4.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US88075507P | 2007-01-16 | 2007-01-16 | |
| PCT/US2008/051214 WO2008089272A1 (en) | 2007-01-16 | 2008-01-16 | Formulations for cancer treatment |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20120960T1 true HRP20120960T1 (hr) | 2012-12-31 |
Family
ID=39350967
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20120960AT HRP20120960T1 (hr) | 2007-01-16 | 2012-11-23 | Formulacije za lijeäśenje raka |
Country Status (33)
| Country | Link |
|---|---|
| US (1) | US20080176946A1 (hr) |
| EP (2) | EP2121139B1 (hr) |
| JP (1) | JP2010516626A (hr) |
| KR (1) | KR20090113852A (hr) |
| CN (1) | CN101668561A (hr) |
| AU (1) | AU2008206294A1 (hr) |
| BR (1) | BRPI0806590A2 (hr) |
| CA (1) | CA2674600A1 (hr) |
| CO (1) | CO6220840A2 (hr) |
| CR (1) | CR10975A (hr) |
| CY (1) | CY1113819T1 (hr) |
| DK (1) | DK2121139T3 (hr) |
| DO (1) | DOP2009000178A (hr) |
| EC (1) | ECSP099577A (hr) |
| ES (1) | ES2395690T3 (hr) |
| GB (1) | GB2447796C (hr) |
| GT (1) | GT200900201A (hr) |
| HK (2) | HK1121697A1 (hr) |
| HR (1) | HRP20120960T1 (hr) |
| IL (1) | IL199682A0 (hr) |
| MA (1) | MA34559B1 (hr) |
| MX (1) | MX2009007596A (hr) |
| NZ (1) | NZ579098A (hr) |
| PL (1) | PL2121139T3 (hr) |
| PT (1) | PT2121139E (hr) |
| RS (1) | RS52633B (hr) |
| RU (2) | RU2481830C2 (hr) |
| SG (1) | SG178714A1 (hr) |
| SI (1) | SI2121139T1 (hr) |
| SV (1) | SV2009003335A (hr) |
| TN (1) | TN2009000292A1 (hr) |
| UA (1) | UA100852C2 (hr) |
| WO (1) | WO2008089272A1 (hr) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7961081B2 (en) * | 2003-05-22 | 2011-06-14 | John Tomlienovic | Anti-theft system and method |
| US20070015814A1 (en) * | 2005-06-10 | 2007-01-18 | Ernest Kun | Parp Modulators and Treatment of Cancer |
| SG164368A1 (en) | 2005-07-18 | 2010-09-29 | Bipar Sciences Inc | Treatment of cancer |
| CA2655257A1 (en) * | 2006-06-12 | 2008-12-04 | Bipar Sciences, Inc. | Method of treating diseases with parp inhibitors |
| US20080262062A1 (en) * | 2006-11-20 | 2008-10-23 | Bipar Sciences, Inc. | Method of treating diseases with parp inhibitors |
| US20100160442A1 (en) * | 2006-07-18 | 2010-06-24 | Ossovskaya Valeria S | Formulations for cancer treatment |
| CA2662337A1 (en) | 2006-09-05 | 2008-03-13 | Bipar Sciences, Inc. | Inhibition of fatty acid synthesis by parp inhibitors and methods of treatment thereof |
| WO2008030892A2 (en) * | 2006-09-05 | 2008-03-13 | Bipar Sciences, Inc. | Drug design for tubulin inhibitors, compositions, and methods of treatment thereof |
| EP2059498A4 (en) | 2006-09-05 | 2011-01-12 | Bipar Sciences Inc | TREATMENT OF CANCER |
| JP2011500684A (ja) * | 2007-10-19 | 2011-01-06 | バイパー サイエンシズ，インコーポレイティド | ベンゾピロン系ｐａｒｐ阻害剤を用いる癌の処置方法および組成物 |
| EP2217227B1 (en) | 2007-11-12 | 2013-08-21 | BiPar Sciences, Inc. | Treatment of breast cancer with 4-iodo-3-nitrobenzamide in combination with anti-tumor agents |
| JP2011521618A (ja) * | 2008-02-04 | 2011-07-28 | バイパー サイエンシズ，インコーポレイティド | Ｐａｒｐ仲介疾患を診断および治療する方法 |
| US8026271B2 (en) * | 2008-07-11 | 2011-09-27 | National Health Research Institutes | Formulations of indol-3-yl-2-oxoacetamide compounds |
| WO2010036226A1 (en) * | 2008-09-26 | 2010-04-01 | George Nelson | Process for treatment of rheumatoid arthritis, tremors/parkinson's disease and multiple sclerosis |
| US20110020392A1 (en) * | 2008-10-14 | 2011-01-27 | Salubrious Pharmaceutical, Llc | Process for treatment of rheumatoid arthritis, tremors/parkinson's disease, multiple sclerosis and non-viral based cancers |
| US20140051737A1 (en) * | 2011-05-10 | 2014-02-20 | Universite Laval | Methods for the treatment and diagnostic of pulmonary arterial hypertension |
| MA38121A1 (fr) * | 2012-11-30 | 2016-10-31 | Glaxosmithkline Llc | Nouvelle composition pharmaceutique |
| US10610590B2 (en) * | 2016-05-02 | 2020-04-07 | Symbios Technologies, Inc. | Electrochemical plasma activated aqueous chemotherapeutics |
| EP3655418A4 (en) | 2017-06-22 | 2021-05-19 | Triact Therapeutics, Inc. | METHOD OF TREATMENT OF GLIOBLASTOMA |
| MX2020003760A (es) | 2017-09-26 | 2020-07-29 | Tesaro Inc | Formulaciones de niraparib. |
| EP3687501A4 (en) * | 2017-09-29 | 2021-06-23 | Triact Therapeutics, Inc. | INIPARIB FORMS AND USES THEREOF |
| WO2020246737A1 (ko) * | 2019-06-04 | 2020-12-10 | 사회복지법인 삼성생명공익재단 | 콰시노이드를 포함하는 거세 저항성 전립선암 치료용 조성물 |
| CZ309587B6 (cs) * | 2021-01-22 | 2023-05-03 | Oncora S.R.O. | Mikroemulzní prekoncentrát s obsahem kladribinu a způsob jeho přípravy |
| GB2611315B (en) * | 2021-09-29 | 2024-01-03 | Siemens Healthcare Gmbh | Method of operating a magnetic resonance scanner |
| WO2023239919A1 (en) * | 2022-06-10 | 2023-12-14 | Dana-Farber Cancer Institute, Inc. | Allelic imbalance of chromatin accessibility in cancer identifies causal risk variants and their mechanisms |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0348655A (ja) * | 1989-07-14 | 1991-03-01 | Shionogi & Co Ltd | プロスタグランジンｄ↓２類の安定化 |
| US5633282A (en) * | 1990-05-25 | 1997-05-27 | British Technology Group Limited | Inhibition of viral infection |
| US5637618A (en) * | 1990-06-01 | 1997-06-10 | Bioresearch, Inc. | Specific eatable taste modifiers |
| US5631038A (en) * | 1990-06-01 | 1997-05-20 | Bioresearch, Inc. | Specific eatable taste modifiers |
| US5232735A (en) * | 1990-06-01 | 1993-08-03 | Bioresearch, Inc. | Ingestibles containing substantially tasteless sweetness inhibitors as bitter taste reducers or substantially tasteless bitter inhibitors as sweet taste reducers |
| US5484951A (en) * | 1990-10-19 | 1996-01-16 | Octamer, Incorporated | 5-iodo-6-amino-6-nitroso-1,2-benzopyrones useful as cytostatic and antiviral agents |
| US5464871A (en) * | 1993-05-12 | 1995-11-07 | Octamer, Inc. | Aromatic nitro and nitroso compounds and their metabolites useful as anti-viral and anti-tumor agents |
| US5516941A (en) * | 1991-10-22 | 1996-05-14 | Octamer, Inc. | Specific inactivators of "retroviral" (asymmetric) zinc fingers |
| US5482975A (en) * | 1991-10-22 | 1996-01-09 | Octamer, Inc. | Adenosine diphosphoribose polymerase binding nitroso aromatic compounds useful as retroviral inactivating agents, anti-retroviral agents and anti-tumor agents |
| US5652260A (en) * | 1991-10-22 | 1997-07-29 | Octamer, Inc. | Adenosine diphosphoribose polymerase binding nitroso aromatic compound useful as retroviral inactivating agents, anti-retroviral agents and anti-tumor agents |
| US5877185A (en) * | 1991-10-22 | 1999-03-02 | Octamer, Inc. | Synergistic compositions useful as anti-tumor agents |
| GB9200247D0 (en) * | 1992-01-07 | 1992-02-26 | Erba Carlo Spa | Pharmaceutical compositions containing polymer derivative-bound anthracycline glycosides and a method for their preparation |
| US5558855A (en) | 1993-01-25 | 1996-09-24 | Sonus Pharmaceuticals | Phase shift colloids as ultrasound contrast agents |
| US6015792A (en) * | 1993-05-26 | 2000-01-18 | Bioresearch, Inc. | Specific eatable taste modifiers |
| US6008250A (en) * | 1993-05-26 | 1999-12-28 | Bioresearch, Inc. | Specific eatable taste modifiers |
| US5589483A (en) * | 1994-12-21 | 1996-12-31 | Geron Corporation | Isoquinoline poly (ADP-ribose) polymerase inhibitors to treat skin diseases associated with cellular senescence |
| WO1996038175A1 (en) * | 1995-06-02 | 1996-12-05 | Takeda Chemical Industries, Ltd. | Stabilized composition comprising an antiulcerative benzimidazole |
| US5837729A (en) * | 1996-04-26 | 1998-11-17 | Metatron, Inc. | Methods for treating and preventing HIV infection using acetaminophen and derivatives thereof |
| CA2286186A1 (en) * | 1997-04-10 | 1998-10-15 | Isotechnika, Inc. | Activated iododerivatives for the treatment of cancer and aids |
| US5908861A (en) * | 1997-05-13 | 1999-06-01 | Octamer, Inc. | Methods for treating inflammation and inflammatory disease using pADPRT inhibitors |
| US6696426B2 (en) * | 2000-08-22 | 2004-02-24 | Pharmacia Corporation | Preservative free ophthalmic oxazolidinone antibiotic drug delivery systems |
| EP1348432A4 (en) * | 2001-01-04 | 2005-08-10 | Daiichi Seiyaku Co | CYCLODEXTRIN-CONTAINING PHARMACEUTICAL COMPOSITION |
| US20050113283A1 (en) * | 2002-01-18 | 2005-05-26 | David Solow-Cordero | Methods of treating conditions associated with an EDG-4 receptor |
| JP2003321364A (ja) * | 2002-05-07 | 2003-11-11 | Eisai Co Ltd | シクロデキストリンにより可溶化及び安定化された抗腫瘍剤含有組成物 |
| EA008438B1 (ru) * | 2003-01-14 | 2007-06-29 | Тева Фармасьютикал Индастриз, Лтд. | Парентеральные композиции пептида для лечения системной красной волчанки |
| WO2005023765A1 (en) * | 2003-09-11 | 2005-03-17 | Pharmacia & Upjohn Company Llc | Method for catalyzing amidation reactions by the presence of co2 |
| US20070015814A1 (en) * | 2005-06-10 | 2007-01-18 | Ernest Kun | Parp Modulators and Treatment of Cancer |
| SG164368A1 (en) * | 2005-07-18 | 2010-09-29 | Bipar Sciences Inc | Treatment of cancer |
| CA2655257A1 (en) * | 2006-06-12 | 2008-12-04 | Bipar Sciences, Inc. | Method of treating diseases with parp inhibitors |
| WO2008030892A2 (en) * | 2006-09-05 | 2008-03-13 | Bipar Sciences, Inc. | Drug design for tubulin inhibitors, compositions, and methods of treatment thereof |
| CA2662335A1 (en) * | 2006-09-05 | 2008-03-13 | Valeria Ossovskaya | Methods for designing parp inhibitors and uses thereof |
| EP2059498A4 (en) * | 2006-09-05 | 2011-01-12 | Bipar Sciences Inc | TREATMENT OF CANCER |
| CA2662337A1 (en) * | 2006-09-05 | 2008-03-13 | Bipar Sciences, Inc. | Inhibition of fatty acid synthesis by parp inhibitors and methods of treatment thereof |
-
2008
- 2008-01-16 RS RS20120544A patent/RS52633B/en unknown
- 2008-01-16 AU AU2008206294A patent/AU2008206294A1/en not_active Withdrawn
- 2008-01-16 CN CN200880008617A patent/CN101668561A/zh active Pending
- 2008-01-16 DK DK08727771.1T patent/DK2121139T3/da active
- 2008-01-16 GB GB0807263A patent/GB2447796C/en not_active Withdrawn - After Issue
- 2008-01-16 US US12/015,403 patent/US20080176946A1/en not_active Abandoned
- 2008-01-16 CA CA002674600A patent/CA2674600A1/en not_active Withdrawn
- 2008-01-16 PT PT87277711T patent/PT2121139E/pt unknown
- 2008-01-16 JP JP2009545734A patent/JP2010516626A/ja not_active Withdrawn
- 2008-01-16 PL PL08727771T patent/PL2121139T3/pl unknown
- 2008-01-16 MA MA32171A patent/MA34559B1/fr unknown
- 2008-01-16 RU RU2009130599/15A patent/RU2481830C2/ru not_active IP Right Cessation
- 2008-01-16 BR BRPI0806590-0A patent/BRPI0806590A2/pt not_active Application Discontinuation
- 2008-01-16 MX MX2009007596A patent/MX2009007596A/es active IP Right Grant
- 2008-01-16 SI SI200830855T patent/SI2121139T1/sl unknown
- 2008-01-16 WO PCT/US2008/051214 patent/WO2008089272A1/en active Application Filing
- 2008-01-16 UA UAA200908564A patent/UA100852C2/ru unknown
- 2008-01-16 NZ NZ579098A patent/NZ579098A/en not_active IP Right Cessation
- 2008-01-16 KR KR1020097017060A patent/KR20090113852A/ko not_active Application Discontinuation
- 2008-01-16 SG SG2012003109A patent/SG178714A1/en unknown
- 2008-01-16 EP EP08727771A patent/EP2121139B1/en active Active
- 2008-01-16 EP EP11192725A patent/EP2476461A3/en not_active Withdrawn
- 2008-01-16 ES ES08727771T patent/ES2395690T3/es active Active
-
2009
- 2009-02-26 HK HK09101870.4A patent/HK1121697A1/xx not_active IP Right Cessation
- 2009-07-02 IL IL199682A patent/IL199682A0/en unknown
- 2009-07-07 TN TNP2009000292A patent/TN2009000292A1/fr unknown
- 2009-07-14 DO DO2009000178A patent/DOP2009000178A/es unknown
- 2009-07-15 SV SV2009003335A patent/SV2009003335A/es unknown
- 2009-07-15 GT GT200900201A patent/GT200900201A/es unknown
- 2009-08-13 EC EC2009009577A patent/ECSP099577A/es unknown
- 2009-08-14 CO CO09085583A patent/CO6220840A2/es not_active Application Discontinuation
- 2009-08-14 CR CR10975A patent/CR10975A/es unknown
-
2010
- 2010-05-24 HK HK10105011.2A patent/HK1137158A1/xx not_active IP Right Cessation
-
2012
- 2012-11-23 HR HRP20120960AT patent/HRP20120960T1/hr unknown
- 2012-12-03 RU RU2012151571/15A patent/RU2012151571A/ru unknown
-
2013
- 2013-01-09 CY CY20131100023T patent/CY1113819T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20120960T1 (hr) | Formulacije za lijeäśenje raka | |
| DE502006006185D1 (de) | Verfahren zur herstellung einer wässrigen suspension und einer pulverförmigen zubereitung eines oder mehrerer carotinoide | |
| RS51185B (sr) | Kompozicije za vaginalnu primenu | |
| WO2009016433A3 (en) | Oncolytic rhabdovirus | |
| HRP20150952T1 (hr) | Određeni triazolopirazini, njihovi pripravci i postupci njihove upotrebe | |
| MD20070267A (en) | Gastroresistant pharmaceutical formulation containing rifaximin | |
| TW200727903A (en) | Stable pharmaceutical compositions of 5, 10 methylenetetrahydrofolate | |
| PT2155188E (pt) | Métodos e composições para o tratamento de cancro recorrente | |
| HRP20110861T1 (hr) | Lijek za liječenje gripe | |
| MX2009004767A (es) | Preparacion liquida que comprende un complejo de pimobendan y ciclodextrina. | |
| TR201905480T4 (tr) | Paklitaksel, paklitaksel analogları veya paklitaksel konjugatlarının farmasötik bileşimleri ve ilgili preparasyon ve kullanım yöntemleri. | |
| NO20080479L (no) | Fremgangsmate for fremstilling av mikrofibrillaer polysakkarid | |
| MX2009013494A (es) | Agente benefico que contiene particulas de suministro. | |
| SG10201804552WA (en) | Nanoparticle compositions, formulations thereof, and uses therefor | |
| WO2012170372A3 (en) | Prna mutlivalent junction domain for use in stable multivalent rna nanoparticles | |
| DK1951730T3 (da) | Heteroalkylbundne pyrimidinderivater | |
| MY158438A (en) | Antibodies against human angiopoietin 2 | |
| WO2008009831A3 (fr) | Derives de cyclodextrines amphiphiles | |
| EA201400193A1 (ru) | Наночастицы оксидных ферримагнетиков со структурой шпинели и наночастицы оксидов железа, биосовместимые водные коллоидные системы, включающие в себя наночастицы, феррилипосомы, и их использование | |
| WO2011003673A3 (de) | Kosmetische zusammensetzungen mit suspensionen von silbersalzen | |
| WO2011116152A3 (en) | Delivery of agents using interfering nanoparticles | |
| EP2328550A4 (en) | MUCOADHERENT COMPOSITIONS AND THEIR USE | |
| MY149924A (en) | Lyophilized preparation comprising influenza vaccine, and method for preparation thereof | |
| RU2014101036A (ru) | Стабилизированная композиция вориконазола | |
| AR088963A1 (es) | Complejo obtenido a partir de mezclas de acido hialuronico o una sal del mismo y sulfato de condroitina |